Ginsenoside Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein

YUN LUO, PING ZHANG, HAN-QING ZENG, SHI-FENG LOU and DAO-XIN WANG

Department of Hematology, Second Affiliated Hospital of Chongqing Medical University, Chongqing 404000, P.R. China

Received August 4, 2014; Accepted April 16, 2015

DOI: 10.3892/mmr.2015.3802

Abstract. Ginsenoside Rg3 is one of the main constituents isolated from Panax ginseng, and exhibits cytotoxic effects against cancer cells. The present study aimed to investigate the effects of ginsenoside Rg3 on human multiple myeloma cells, and determine the underlying molecular mechanisms. The cells were exposed to ginsenoside Rg3 at various concentrations (0-80 µM) for 48 h. A subsequent cell proliferation assay demonstrated that treatment with ginsenoside Rg3 resulted in a dose-dependent inhibition of the proliferation of U266 and RPMI8226 cells. Furthermore, exposure to ginsenoside Rg3 led to a marked increase in the rate of apoptosis in the U266 cells, coupled with increased caspase-3 activity. The ginsenoside Rg3-treated cells also exhibited an elevation in the expression of B-cell lymphoma 2-associated X protein (Bax), a pro-apoptotic protein. Notably, knockdown of Bax protected the U266 cells from Rg3-induced apoptosis. Overall, these findings suggested that ginsenoside Rg3 induced apoptosis in multiple myeloma cells, at least partially, through upregulation of the expression of Bax.

Introduction

Multiple myeloma is a plasma cell neoplasm, characterized by the overgrowth of mature antibody-producing plasma cells in the bone marrow. Multiple myeloma ranks as the second most common type of hematologic malignancy, following non-Hodgkin's lymphoma, with >20,000 new cases diagnosed annually in the USA. Despite advances in the treatment of multiple myeloma, the disease remains incurable, with a median survival rate of between 3 and 5 years (1). Patients with multiple myeloma eventually succumb to recurrent or refractory disease; therefore, there is an urgent requirement for the identification of novel effective agents for the treatment of multiple myeloma.

Apoptosis, also termed programmed cell death, is morphologically distinct from necrotic cell death. Apoptotic cells typically exhibit chromatin condensation, the formation of apoptotic bodies and an intact cell membrane (2). There are two predominant apoptotic pathways: The extrinsic, or death receptor, pathway and the intrinsic, or mitochondrial, pathway (3). These two pathways converge on the activation of caspases, which are responsible for the execution of apoptosis through the cleavage of structural and regulatory cellular proteins and nuclear DNA. The mitochondrial pathway is primarily regulated by members of the B-cell lymphoma 2 (Bcl-2) family, which comprises pro-apoptotic proteins, including Bcl-2-associated X protein (Bax), and anti-apoptotic proteins, including Bcl-2 and Bcl-extra large (Bcl-XL) (4). Resistance to apoptosis is important in the pathogenesis of multiple myeloma, which involves the activation of multiple survival pathways, including nuclear factor-κB (NF-κB), Janus kinase 2/signal transducers and activators of transcription (3), and phosphoinositide 3-kinase/Akt (5).

Ginseng, the root of Panax ginseng C.A. Meyer, is a herbal plant, which has received increasing attention due to its various pharmacological properties, including antitumor (6) and antioxidant properties (7). Ginsenoside Rg3 is one of the predominant constituents isolated from Panax ginseng, which exhibits cytotoxic effects against a wide range of cancer cells (8,9). Keum et al (10) reported that the antitumor activity of ginsenoside Rg3 in HL-60 human pro-myelocytic leukemia cells is partially mediated through the downregulation of NF-κB. In colon (8) and prostate (9) cancer cells, ginsenoside Rg3 is also capable of suppressing the activation of NF-κB, consequently enhancing the susceptibility of cancer cells to chemotherapeutic drugs (10). Despite evidence for the anticancer activity of ginsenoside Rg3, its actions in multiple myeloma remain to be fully elucidated.

The present study aimed to determine the effects of ginsenoside Rg3 treatment on human multiple myeloma cells, and investigate the possible underlying molecular mechanisms.

Materials and methods

Reagents. Ginsenoside Rg3, with a purity of >98%, was purchased from Jilin Yatai Pharmaceutical Company.
(Changchun, China). Dimethyl sulfoxide (DMSO) and 4,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was purchased from GE Healthcare Life Sciences (Logan, UT, USA). RPMI 1640 medium was purchased from Invitrogen Life Technologies (Carlsbad, CA, USA), the Annexin V/PE Apoptosis Assay kit was obtained from Shenzhen Genmed Biological Company (Shenzhen, China) and the Caspase-3 Activity Assay kit was purchased from EMD Millipore (Billerica, MA, USA). Mouse monoclonal antibodies targeting Bax (mouse; cat no. Ab122; 1:800) and GAPDH were purchased from Beyotime Institute of Biotechnology (Shanghai, China). Horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (cat. no. ZDR-5307; 1:1,000) was obtained from Beijing Zhongshan-Golden Bridge Biological Company (Beijing, China).

**Cells and culture.** The U266 and RPMI8226 human multiple myeloma cells were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China) and cultured in RPMI 1640 medium, supplemented with 10% heat-inactivated FBS, 1% penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). The cells were maintained in a humidified incubator at 5% CO₂ and 95% air at 37°C, and were passaged every 3-4 days.

**Small interfering (si)RNA transfection.** The U266 cells were seeded into six-well plates at a confluence of 40%. The cells were subsequently transfected with siRNA using Lipofectamine 2000 (Invitrogen Life Technologies), according to the manufacturer's instructions.

**Cell proliferation assay.** The effects of ginsenoside Rg3 on cell proliferation were determined using an MTT assay (Beyotime Institute of Biotechnology, Shanghai, China). Briefly, the U266 cells or RPMI8226 cells were seeded into 96-well plates at a density of 1x10⁵ cells/well (100 µl) and were exposed to ginsenoside Rg3 at different concentrations (20, 40 or 80 µM) in RPMI 1640 medium supplemented with 10% FBS. Control cells were treated with the medium only. Following treatment for 48 h at 37°C, MTT solution at a final concentration of 0.5 mg/ml was added to the cells in each well. After 2 h incubation at 37°C, 150 µl DMSO was added to each well, in order to dissolve the blue formazan crystals. The optical densities (OD) of the cells were measured at a wavelength of 545 nm, with a reference wavelength of 650 nm. The cell proliferation inhibitory rate was calculated using the following formula: Inhibitory rate (%) = (1 - mean OD of experiment group / mean OD of control group) x 100.

**Analysis of apoptosis using annexin-V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) with flow cytometry.** The U266 cells, exposed to various concentrations of ginsenoside Rg3 for 48 h, were harvested by trypsinization and washed twice with cold PBS. The cells were then centrifuged at 200 x g for 5 min and the cell pellet was resuspended in 1X binding buffer, containing 10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl₂, at a density of 1x10⁶ cells/ml. The sample solution (100 µl) was transferred to a 5 ml culture tube and incubated with FITC-conjugated annexin V and PI for 15 min at room temperature in the dark. The 1X binding buffer (400 µl) was added to each sample tube, and the samples were analyzed on a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA) using Cell Quest Research software version 3.3 (BD Biosciences).

**Western blot analysis.** Following treatment with ginsenoside Rg3, the cells were lysed in lysis buffer, containing 50 mmol/l tris (pH 7.4), 150 mmol/l NaCl; 1% NP-40 and 0.1% SDS (Sangon Biotech, Inc.), supplemented with 1X protease and phosphatase inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). The protein samples were then separated on polyacrylamide gels containing 0.1% SDS and then transferred to a nitrocellulose membrane (GE Healthcare Life Sciences). The membrane was then blocked for 4 h at 37°C in tris-buffered saline (TBS) containing 5% fat-free dried milk and 0.5% Tween-20, following which the membrane was incubated with individual antibodies targeting Bax overnight at 4°C. The membrane was then washed three times with TBS and incubated for 1 h with secondary antibodies at room temperature. The signals were visualized using enhanced chemiluminescence and developed on X-ray film (Carestream Health, Inc., Rochester, NY, USA). The band density was measured using the GEL DOC 2000 system equipped with Quantity One software (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and normalized against the density of β-actin.

**Reverse transcription quantitative polymerase chain reaction (RT-qPCR).** The total RNA was extracted using TRizol Reagent (Invitrogen Life Technologies), according to the manufacturer's instructions. The cDNA was synthesized from 1 µg total RNA using an iScript™ cDNA Synthesis kit (Bio-Rad, Richmond, CA, USA). Relative gene expression levels were determined using FastStart Universal SYBR Green Master mix (Roche Diagnostics), with the mRNA expression levels of β-actin used as an endogenous control. The expression levels of the target genes were calculated using the 2⁻ΔΔCt method.

**Caspase-3 activity assay.** The activity of caspase-3 was determined using a colorimetric assay kit. The U266 cells at 60% confluence, treated with various concentrations of ginsenoside Rg3, were washed with PBS, and lysed in caspase-3 sample lysis buffer. The cell lysates were then centrifuged at 12,000 x g for 20 min at 4°C, and the resulting supernatants were assessed for protein concentration and caspase-3 activity. The protein concentration was determined using a Bicinchoninic Acid Protein Assay kit (Sigma-Aldrich). The cell lysates were incubated in reaction buffer containing a caspase-3 specific inhibitor (z-DEVD-FMK-pNA; 20 mmol/l) for 4 h at 37°C. The absorbance was measured at a wavelength of 405 nm. Each sample was assessed in triplicate.

**Statistical analysis.** All data are expressed as the mean ± standard deviation. Statistical significance was determined using Student's t-test on SPSS 19.0 software (IBM SPSS, Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Effects of ginsenoside Rg3 on the viability of human multiple myeloma cells. To determine whether ginsenoside Rg3 affected cancer cell growth in culture, an MTT assay was performed on U266 and RPMI8226 cells treated with increasing concentrations of Rg3 (0, 10, 20, 40 and 80 µM) for 48 h. Treatment with ginsenoside Rg3 resulted in a dose-dependent inhibition of cell proliferation in the two cell lines, compared with the untreated control cells (Fig. 1A). The half maximal inhibitory concentration of ginsenoside Rg3 was ~40 µM in the U266 cells and 70 µM in the RPMI8226 cells. The highest inhibitory rate was observed at a concentration of 80 µM for 48 h in the two cell lines. When the cell lines were treated with 40 µM Rg3 for 0, 24, 48 and 72 h, the cell viability declined significantly after 24 h (P<0.005, vs. control; Fig. 1B).

Ginsenoside Rg3 induces apoptosis in U266 cells. To determine whether the antiproliferative effects of Rg3 were associated with the induction of apoptosis, the U266 cells were treated with 0-40 µM Rg3. The rate of Rg3-induced apoptosis was determined in the U266 cells using annexin-V/PE staining. As shown in Fig. 2A, treatment with Rg3 at 10, 20 and 40 µM caused a significant increase in apoptosis, (16.2±0.46, 22.1±0.83 and 33.2±0.18%, respectively) compared with the untreated control cells (5.70±0.10%; P<0.05). Caspase-3 is universally activated during apoptotic cell death by the extrinsic (death ligand) and intrinsic (mitochondrial) pathways. To determine whether the caspase cascade mediated Rg3-induced apoptosis, caspase-3 activity was examined using pNA. The activity of caspase-3 was significantly higher in the Rg3 (60 µM)-treated cells, compared with the untreated control cells (Fig. 2B). Furthermore, caspase-3 activity was significantly decreased when the U266 cells were pretreated with z-DEVD-FMK, a caspase-3 inhibitor (Fig. 2C). Pre-treatment with z-DEVD-FMK attenuated the increased rate of apoptosis in the Rg3-treated cells, suggesting that Rg3 induced apoptosis in the U266 cells via the caspase-3-dependent apoptotic pathway (Fig. 2D).

Ginsenoside Rg3 enhances the expression levels of Bax. The Bcl-2 family is important in apoptosis in leukemogenesis. To investigate the molecular mechanism underlying Rg3-induced apoptosis, the Bcl-2 family proteins were examined. The U266 cells were treated with different concentrations of ginsenoside Rg3. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) demonstrated that treatment with 20-80 µM ginsenoside Rg3 resulted in upregulated mRNA expression levels of Bax (Fig. 3A). Western blot analysis...
revealed that exposure to various concentrations of ginsenoside Rg3 resulted in a marked reduction in the expression levels of Bax (Fig. 3B). These results suggested that treatment with ginsenoside Rg3 enhanced the expression of Bax at the transcriptional level.

**Bax mediates the pro-apoptotic effects of ginsenoside Rg3.**

To determine whether Bax was essential for caspase-3 activation, the U266 cells were transfected with small interfering (si)RNA targeting Bax prior to Rg3 treatment. Transfection of the cells with Bax-siRNA efficiently knocked down the expression of Bax in the U266 cells (Fig. 4A). Furthermore, BAX knockdown also protected the U266 cells from Rg3-induced apoptosis, indicating that Rg3-induced apoptosis was partially due to upregulation of Bax (Fig. 4B). These data suggested that Rg3 induced apoptosis in human multiple myeloma cells, at least in part, via the Bax-dependent activation of caspase-3.
**Figure 3.** Treatment with ginsenoside Rg3 regulates the expression of Bax. (A) mRNA expression levels of Bax in U266 human multiple myeloma cells treated with 20-80 µM ginsenoside Rg3 for 48 h. Analysis was performed using reverse transcription-quantitative polymerase chain reaction (*P<0.05). (B) Western blot analysis of the protein expression levels of Bax in Rg3-treated U266 cells. β-actin was used as a loading control. Data are expressed as the mean ± standard deviation (*P<0.01). Bax, B-cell lymphoma 2-associated X protein.

**Figure 4.** Bax is associated with ginsenoside Rg3-induced apoptosis. (A) Western blot analysis of the expression of Bax in U266 human multiple myeloma cells transfected with siRNA control or siRNA Bax. β-actin was used as a loading control. (B) Bax knockdown eliminated Rg3-induced apoptosis. U266 cells were transfected with siRNA or siRNA Bax and then treated with Rg3 (40 µM) prior to flow cytometry. Bax, Bel 2-associated X protein; siRNA, small interfering RNA; PI, propidium iodide.
Discussion

The results of the present study demonstrated that exposure to ginsenoside Rg3 resulted in the dose-dependent inhibition of cell proliferation in the U266 and RPMI8226 cell lines. The anti-proliferative effect of ginsenoside Rg3 has been documented in other types of cancer cell, including HCC and colon cancer cells (11,12). These findings indicate that ginsenoside Rg3 exhibited growth-suppressive activity in solid and hematologic malignancies. The induction of apoptosis is an important mechanism of antitumor agents. As apoptosis proceeds without disruption of plasma membrane integrity, it prevents the onset of an inflammatory response, which favors tumor progression (13). Therefore, inducing apoptosis, rather than necrosis, has been regarded as a preferred and superior strategy for clearing tumor cells. Notably, the present study demonstrated, using DAPI staining, that treatment with ginsenoside Rg3 led to apoptotic morphological changes, including nuclear condensation and fragmentation, and the formation of apoptotic bodies in the U266 cells. The results of the annexin-V/PI staining further confirmed the apoptosis-promoting role of ginsenoside Rg3. These results suggested that the antiproliferative activity of ginsenoside Rg3 in multiple myeloma cells is associated with the induction of apoptosis. Ginsenoside Rg3 has also been reported to suppress tumor growth by inducing tumor cell apoptosis in HCC (14).

Caspases are a family of proteases, which regulate apoptosis. The caspase family includes upstream initiator caspases, including caspase-8 and 10, and downstream executor caspases, including caspase-3. It is widely accepted that activation of caspase-3 is essential for triggering apoptosis in several types of cell (2). Brazilin, which is isolated from Caesalpinia sappan, has been reported to promote apoptosis in U266 multiple myeloma cells through the activation of caspase-3 (15). To further investigate the possible mechanism underlying Rg3-induced apoptosis in human multiple myeloma, the present study examined the activity of caspase-3 in Rg3-treated cells. The data revealed that ginsenoside Rg3-induced apoptosis involved the activation of caspase-3 in the U266 cells, in a dose-dependent manner. In order to confirm the importance of caspase-3 for Rg3-induced apoptosis, the U266 cells were pretreated with an irreversible caspase-3 inhibitor. Rg3-induced apoptosis was decreased following the inhibition of caspase-3 activation, suggesting that Rg3-induced apoptosis was caspase-3 dependent. Bcl-2 family members exhibit either pro- or anti-apoptotic activities, and regulate the mitochondrial pathway of apoptosis by controlling the permeabilization of the outer mitochondrial membrane (16). Activated Bax is involved in the formation of pores in the outer mitochondrial membrane, which allow the release of cytochrome c from the mitochondria, consequently leading to activation of caspases (16). The present study demonstrated that exposure to ginsenoside Rg3 resulted in a marked enhancement of the mRNA and protein expression levels of Bax. Notably, silencing the expression of Bax reduced the activation of caspase-3 and the levels of apoptosis in the Rg3-treated U266 cells. These findings collectively suggested that ginsenoside Rg3 induced apoptosis in human multiple myeloma cells by modulating the expression of Bax, which triggered the caspase-3-dependent pathway. Activation of the mitochondrial pathway of apoptosis by ginsenoside Rg3 has also been documented in HCC (14-17) and colon cancer cells (12).

In conclusion, the present study demonstrated that ginsenoside Rg3 inhibited the proliferation and induced the apoptosis of human multiple myeloma cells. Furthermore, Rg3-induced apoptosis was partially due to upregulation of Bax. However, there were certain limitations to the present study. The detailed signaling pathways involved in ginsenoside Rg3-induced apoptosis in multiple myeloma cells require further elucidation. In addition, whether these findings can be translated into the clinical setting remains to be elucidated. Therefore, further investigation is required to assess the possible therapeutic application of ginsenoside Rg3 in human multiple myeloma therapy.

References